Abstract
Adjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long-term survival. In the mid-1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5-fluorouracil-based chemoradiation and now the PRODIGE trial showed the benefit of FOLFIRINOX with the longest overall survival to date approaching 5 years. Further investigation on the agents, duration and sequencing of therapy remains ongoing.
Original language | English (US) |
---|---|
Pages (from-to) | 1467-1474 |
Number of pages | 8 |
Journal | Journal of surgical oncology |
Volume | 123 |
Issue number | 6 |
DOIs | |
State | Published - May 1 2021 |
Keywords
- adjuvant chemoradiation
- adjuvant chemotherapy
- evidence-based medicine
- pancreatic cancer
ASJC Scopus subject areas
- Surgery
- Oncology